Sign up to save your podcasts
Or
Share Big data in pharma - From garbage to gold
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Big data in pharma - From garbage to gold
The biorevolution podcast #15
In our data-heavy age, data becomes a treasure, a currency, a valuable good. This is true especially for the biotech and pharmaceutical industries, where data can inform the development of novel drugs. But should own biomedical data – and where should the lines between privacy and patient benefit be drawn?
In the new episode of We’re doomed, we’re saved, Andreas Horchler and Louise von Stechow discuss new strategies of data sharing and ownership in biomedicine and pharma.
Content and Editing:
Louise von Stechow and Andreas Horchler
Disclaimer:
Louise von Stechow, Andreas Horchler and their guests express their personal opinions, which are founded on research on the respective topics, but do not claim to give medical, investment or even life advice in the podcast.
Learn more about the future of biotech in our podcasts and keynotes. Contact us here:
scientific communication: https://science-tales.com/
Podcasts: https://www.podcon.de/
Keynotes: https://www.zukunftsinstitut.de/louise-von-stechow
Image:
Sigmund al4RJ- via Unsplash
References:
https://www.biopharminternational.com/view/big-pharma-meets-big-data
https://www.forbes.com/sites/forbesbusinesscouncil/2022/05/27/data-is-pharmas-next-blockbuster/
https://www.melloddy.eu/
https://www.pistoiaalliance.org/eventdetails/pistoia-alliances-2023-annual-usa-conference/
https://spectrum.ieee.org/icelands-giant-genome-project-points-to-future-of-medicine
https://academic.oup.com/jlb/article/8/2/lsab023/6380070
View all episodes
By Louise von StechowThe biorevolution podcast #15
In our data-heavy age, data becomes a treasure, a currency, a valuable good. This is true especially for the biotech and pharmaceutical industries, where data can inform the development of novel drugs. But should own biomedical data – and where should the lines between privacy and patient benefit be drawn?
In the new episode of We’re doomed, we’re saved, Andreas Horchler and Louise von Stechow discuss new strategies of data sharing and ownership in biomedicine and pharma.
Content and Editing:
Louise von Stechow and Andreas Horchler
Disclaimer:
Louise von Stechow, Andreas Horchler and their guests express their personal opinions, which are founded on research on the respective topics, but do not claim to give medical, investment or even life advice in the podcast.
Learn more about the future of biotech in our podcasts and keynotes. Contact us here:
scientific communication: https://science-tales.com/
Podcasts: https://www.podcon.de/
Keynotes: https://www.zukunftsinstitut.de/louise-von-stechow
Image:
Sigmund al4RJ- via Unsplash
References:
https://www.biopharminternational.com/view/big-pharma-meets-big-data
https://www.forbes.com/sites/forbesbusinesscouncil/2022/05/27/data-is-pharmas-next-blockbuster/
https://www.melloddy.eu/
https://www.pistoiaalliance.org/eventdetails/pistoia-alliances-2023-annual-usa-conference/
https://spectrum.ieee.org/icelands-giant-genome-project-points-to-future-of-medicine
https://academic.oup.com/jlb/article/8/2/lsab023/6380070